A Phase 1, First-in-Humans, safety study of SNSP113 in patients with Cystic Fibrosis.

Trial Profile

A Phase 1, First-in-Humans, safety study of SNSP113 in patients with Cystic Fibrosis.

Planning
Phase of Trial: Phase I

Latest Information Update: 29 Jun 2017

At a glance

  • Drugs SYGN 113 (Primary)
  • Indications Cystic fibrosis
  • Focus Adverse reactions; First in man
  • Most Recent Events

    • 29 Jun 2017 Acoording to Synspira Media Release, this trail will initiate in early 2018.
    • 10 Nov 2016 New trial record
    • 27 Oct 2016 According to a Synedgen media release, the company expects to initiate this study in the year 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top